NareshBummaMD

PubMed

• Hereditary Transthyretin Amyloidosis in Patients Referred to a Genetic Testing Program.
  Kunal Bhatt, Diego H Delgado, Sami Khella, Naresh Bumma, Chafic Karam
  Journal of the American Heart Association. 2024-12-03
• A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed mul...
  Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves
  Future Oncology. 2024-10-25
• 6 citations
  Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
  Naresh Bumma, Joshua Richter, Sundar Jagannath, Hans C Lee, James E Hoffman
  Journal of Clinical Oncology. 2024-08-01

Journal Articles

• Daratumumab proves safe and highly effective in AL amyloidosis  
  Khouri, J., Kin, A., Thapa, B., Reu, F. J., Bumma, N., Samaras, C. J., ... & Faiman, B. M., British journal of haematology, 1/1/2018
• Neutrophil lymphocyte ratio (NLR) as a clinical biomarker predictive of outcomes with immune checkpoint inhibitor therapy in genitourinary cancers  
  Jeyakumar, G., Bumma, N., Kim, S., Landry, C., Kim, H., Silski, C., ... & Vaishampayan, U. N., Journal of Clinical Oncology, 1/1/2017
• Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia  
  Bumma N, Papadantonakis N, Advani S.A., Future Oncology, 1/1/2015
• The efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antitubercul...  
  Sinha S, Dhooria S, Bumma N, AIDS Res Ther, 1/1/2011
• Join now to see all

Abstracts/Posters

• The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis
  Naresh Bumma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
  Naresh Bumma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Improvement in Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience
  Naresh Bumma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• AL Amyloidosis: The Effects of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes
  Naresh Bumma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Neutrophil lymphocyte ratio (NLR) as a clinical biomarker predictive of outcomes with immune checkpoint inhibitor therapy in genitourinary cancers.
  Jeyakumar, G., Bumma, N., Kim, S., Landry, C., & Vaishampayan, U. N., 1/1/2017
• Neutrophil lymphocyte ratio (NLR) as a predictive biomarker for PD-1/PD-L1 directed therapy in metastatic non-small cell lung cancer.
  Bumma, N, et al, 1/1/2017
• Effect of lenalidomide use as part of induction chemotherapy on the risk of peri-transplant venous thromboembolic events (VTE) in patients undergoing autologous stem c...
  Bumma, N., Peravali, M., Jeyakumar, G., Kim, S., Alavi, A., Bhutani, D., ... & Deol, A, 1/1/2017
• Effect of Intravenous versus Subcutaneous Bortezomib in Amyloidosis
  Bumma N, Valent J, 19th Annual Medicine Scholarly Activity Day at Cleveland Clinic Foundation, 1/14/2014
• Safety and Efficacy of Once Weekly Subcutaneous Bortezomib in Advanced Stage AL Amyloidosis
  Bumma N, et al, Blood, 1/1/2014
• Impact of Day 28 Absolute Lymphocyte Count on Outcome of Adult Patients with Acute Myeloid Leukemia
  Bumma N, et al, Blood, 1/1/2014
• Comparison of Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma (BCL-U) P...
  Bumma N, et al, Blood, 1/1/2014
• Join now to see all

Lectures

• Phase II Study of Anti-CD3 x Anti-HER2/neu (Her2Bi) Armed Activated T Cells (ATC) after Neoadjuvant Chemotherapy in Patients with HER2/neu (0-2+)-Negative Stage II-III... 
  Detroit, MI - 1/11/2017
• Once weekly subcutaneous bortezomib based induction therapy in AL amyloidosis 
  Indianapolis, IN - 1/27/2014